

Canaccord Genuity
Digital & Tech-Enabled
Health Snapshot

Q4'23 Update



## **Table of Contents**

A. Canaccord Genuity Digital & Tech-Enabled Health Credentials

B. Digital & Tech-Enabled Health Market Update

Appendix: Select Q4'23¹ Transactions



Canaccord Genuity
Digital & Tech-Enabled
Health Credentials

Section A



## **Canaccord Genuity is a Premier Investment Bank for Growth Companies**

## Global and Integrated Full-Service Platform

## Deep Digital & Tech-Enabled Health Expertise



Behavioral Health



**Benefits** Management



Care Coordination Chronic Disease & Navigation



Management



Software



Data & Insights



Employer-Sponsored Health



Next-Gen **Primary Care** 



Patient Financial



Engagement Commercialization



Physician **Enablement** 



Provider Marketing



Revenue Cycle Technology



Telemedicine & Virtual Care



Workforce Management

## **Investment Banking**

- 280+ investment bankers globally
- Led or participated in 359 transactions, raising over \$17.5 billion in FY 2023
- Solely focused on growth stories
- Listing capabilities on 10 stock exchanges worldwide

## **Equity Research**

- 115+ research professionals
- Broad industry coverage across core sectors
- 860+ companies covered
- Quest® online valuation tool with 95% global coverage

## Sales and Trading

- Equities and fixed income
- 155+ sales and trading professionals
- 15+ fixed income professionals
- 3.000+ institutions covered
- Market making
  - 2,500+ companies



Thomas P. O'Connor Managing Director & Co-Head of Healthcare **New York** 



Matthew Kebel Managing Director **Vew York** 



Fred Fang Nashville



Rob Higham



Henry Hamlin Nashville

## Leading Mid-Market Digital & Tech-Enabled Health M&A Advisor

Dedicated M&A team with deep transaction experience across sectors and geographies

Digital & Tech-Enabled Health Sell-Side Advisory<sup>1</sup>

Rank	Firm Name	Transactions 2018 – 2023
1	Canaccord Genuity	63
2	TripleTree	62
3	William Blair	52
4	Ziegler	33
5	Houlihan Lokey	32
6	Brentwood Capital	24
7	Raymond James	23
8	Piper Sandler	22
9	Healthcare Growth Partners	20
10	Baird	19
11	Lincoln International	17
11	Cain Brothers	17
13	Bailey & Company	16
13	Harris Williams	16
15	Evercore	14

#### Select Healthcare Transactions









**DCP** ♦♦♦



MIROCULUS

Financial Advisor

on sale to

INTEGR∧

March 2023



III Health

Financial Advisor

on sale to

REAL CHEMISTRY

March 2023





Perspecta<sup>\*</sup>

Financial Advisor

on growth

recapitalization by

Fifth Century Partners

January 2023



Financial Advisor

on sale to

December 2022











eråotr































June 2022

Financial Advisor on sale to









May 2021

W chartwise

5 Driven by your success.

Source: Canaccord Genuity database

## **Leading Global Underwriter Since 2022**

CG finished December as the leading global underwriter and a top global bookrunner since 2022

- Leveraging our global capabilities, CG ranks as the leading global underwriter and one of the top global bookrunners since 2022
- Underwriter on 652 total financings; Bookrunner on 517
- Transactions across US, Canada, Australia, & UK platforms

## Select CG Financings



\$152,700,000 Follow-on Offering Co-Manager December 2023



£8,520,000 Follow-on Offering Joint Bookrunner December 2023



\$747,500,000 Conv. Notes Offering Co-Manager December 2023



C\$23,490,000 Follow-on Offering Joint Bookrunner December 2023



A\$205,000,000 Follow-on Offering Joint Bookrunner December 2023



\$261,620,000 Follow-on Offering Joint Bookrunner November 2023



C\$56,010,000
Follow-on Offering
Joint Bookrunner
October 2023



\$100,160,000 Private Placement Co-Placement Agent October 2023



A\$300,000,000 Follow-on Offering Joint Bookrunner October 2023



\$576,000,000 Initial Public Offering Co-Manager September 2023



£102,850,000 Follow-on Offering Joint Bookrunner September 2023



C\$38,830,000 Follow-on Offering Sole Bookrunner September 2023 Global League Table (US-Focused Banks)

Global	David.	l otal	Bookrun	lotal
Rank	Bank	Deals	Deals	Proceeds
				(\$M)
1	Canaccord Genuity	652	517	24,801.0
2	JPMorgan	568	553	284,833.1
3	Goldman Sachs	530	514	305,358.8
4	BofA Securities	489	464	287,508.4
5	Morgan Stanley	484	466	258,424.3
6	Citi	389	377	246,992.7
7	UBS	359	345	147,801.4
9	Jefferies	279	277	81,716.8
10	Barclays	259	246	142,127.5
11	Stifel	257	166	60,944.9
12	HC Wainwright	251	193	8,741.8
13	RBC Capital Markets	250	200	93,531.2
15	Raymond James & Associates	226	109	36,407.9
16	BMO Capital Markets	222	137	61,743.1
24	Maxim Group	161	141	4,321.2
26	Wells Fargo	145	129	86,024.6
32	Deutsche Bank	133	122	98,057.1
36	AGP/Alliance Global Partners	124	116	2,987.8
38	Piper Sandler	121	101	29,668.5
42	Leerink Partners	109	104	24,942.6
44	Cantor Fitzgerald	107	83	13,745.7
48	Truist Financial	96	81	42,045.1
50	Evercore	91	90	36,904.6
50	Roth Capital Partners	91	54	8,754.6
54	EF Hutton	89	86	3,415.5
62	BTIG	78	25	26,372.2




Digital & Tech-Enabled Health Market Update

Section B



## **Share Performance and Valuation Summary**



Carrinary Cadabatics								
	Share Perf	ormance	EV / 2023E					
i	CY'23 <sup>1</sup>	Q4'23	Revenue	EBITDA <sup>2</sup>				
NASDAQ	44.5%	12.8%	N/A	N/A				
S&P 500	24.7%	11.2%	N/A	N/A				
Virtual Care and Digital Health	24.3%	20.0%	2.1x	19.0x				
Pharma	11.2%	10.3%	6.8x	22.6x				
Employer	5.2%	7.3%	2.4x	13.0x				
Payor	(2.3%)	7.2%	2.0x	12.0x				
Next-Gen Primary Care	(8.7%)	(15.6%)	1.1x	20.3x				
Provider	(18.0%)	(2.9%)	3.2x	14.1x				

Summary Statistics

Past performance is not a guarantee of future results. Index returns are unmanaged, and do not include the deduction of fees or other expenses.

#### Commentary

- Q4'23 represented the first quarter since Q2'22 with total global M&A transaction value greater than \$1.0 trillion. Further, the healthcare sector represented 14% of the total global M&A activity in 2023, an increase from 9% in 2022
- After four interest rate hikes during the first three quarters of 2023, the Federal Reserve chose to hold interest rates steady at their final meeting of CY'23. Q4'23 represented the first quarter since 2021 where the Federal Reserve did not increase interest rates at least once during the quarter
- Digital & Tech-Enabled Health stocks strengthened throughout the final quarter of 2023 on the heels of an improved market backdrop and optimistic outlook on interest rates
- The Virtual Care and Digital Health, Pharma and Employer stock indices all finished the year in positive territory, but lagged behind the NASDAQ and S&P 500
- Despite the lower stock performance of the Provider public peer group, M&A demand remains strong in this particular sector with half of all the Digital & Tech-Enabled Health M&A transactions in Q4'23 occurring within this group, with two disclosed transactions over \$1B enterprise value

the following slides

Peer Group indices are based on constituents listed on slides 9 - 14 and performance is market cap weighted. Refer to the definitions on

Source: S&P Capital IQ and Dealogic as of 12/31/23;

Projections based off consensus analyst estimates

Calendar Year 2023 – "CY'23"


Earnings before interest, taxes, depreciation and amortization – "EBITDA"

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and
includes companies based outside the United States – "Nasdaq"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries—"S&P 500"

## **Virtual Care and Digital Health Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Nov-23	Fern Health	BehaVR	M&A	N/D	Companies will merge to form RealizedCare, a digital care management platform for chronic pain powered by digital therapeutics technology
Nov-23	Cloudbreak Health	GTCR	M&A	\$180	Offers a communication and translation platform that provides patients and providers with video remote interpreting telehealth technology
Oct-23	Signos	Cheyenne Ventures / Google Ventures	Series B	\$20	Delivers a metabolic health platform that includes a proprietary Al-engine with continuous glucose monitoring and real-time data $\frac{1}{2} \left( \frac{1}{2} \right) = \frac{1}{2} \left( \frac{1}{2} \right) \left( \frac{1}$
Oct-23	Allara	Google Ventures	Series A	\$10	Provides a telehealth platform for women dealing with reproductive aging and chronic hormonal conditions
Oct-23	Bright.MD's Technology Platform	Evernorth Health	M&A	N/D	Offers an Al-powered care automation platform that allows patients to navigate and receive care for hundreds of low-acuity medical conditions

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

M&A Transaction Value represents Enterprise Value at announcements; \$USD in millions - "M"; Not disclosed values - "N/D"


The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdag"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the properties of the prop

broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the secondA Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to

## **Pharma Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Nov-23	IntegriChain	Nordic Capital	M&A	N/D	Provides solutions to help connect the commercial, financial and operational dimensions of drug access and profitability
Nov-23	CrowdPharm	Spectrum Science	M&A	N/D	Offers healthcare advertising through innovative technology that provides original strategic and creative solutions
Nov-23	ConcentricLife	Accenture	M&A	\$245	Offers healthcare marketing solutions with expertise in helping life sciences companies build an optimal brand experience
Oct-23	BioProcure and Prendio	Primus Capital	Growth Investment	N/D	Together provide procure-to-pay services and cloud-based SaaS eProcurement software for biotech and life sciences companies
Oct-23	• Medicx Health	OptimizeRx	M&A	\$95	Provides healthcare consumer-focused omnichannel marketing and analytics to drive engagement

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

M&A Transaction Value represents Enterprise Value at announcements

Indicates a Canaccord Genuity-led transaction


The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdag"

 $Standard \ and \ Poor's 500 \ Index \ is \ a \ capitalization-weighted \ index \ of 500 \ stocks. The \ index \ is \ designed \ to \ measure \ performance \ of the$ 

broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the secondA Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to

## **Employer Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Dec-23	Employer Direct Healthcare	Insight Partners	Secondary	\$92	Offer a specialty healthcare network solution for self-funded employers with a focus on surgical care and oncology
Dec-23	Medefy Health	Mercury Fund	Series A	\$10	Offers a mobile-first healthcare benefits navigation platform dedicated to improving the employee health benefits experience
Nov-23	Navigate Wellbeing Solutions	McCarthy Capital	Capital Raise	N/D	Offers wellness technology that transforms how organizations improve their employees' wellbeing and engagement
Nov-23	Vida Health	General Atlantic / Ally Bridge / Canvas Ventures	Capital Raise	\$29	Provides virtual cardiometabolic care focused on treating diabetes and obesity through clinically validated programs
Nov-23	SentryHealth	First Stop Health	M&A	N/D	Provides care navigation solutions that combine data, technology and an experienced care team to match members with the best care

the left of the chart. Performance is market cap-weighted

A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

M&A Transaction Value represents Enterprise Value at announcements

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdag"

 $Standard \ and \ Poor's 500 \ Index \ is \ a \ capitalization-weighted \ index \ of 500 \ stocks. The \ index \ is \ designed \ to \ measure \ performance \ of \ the$ broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the second

## **Payor Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Dec-23	Decision Point and HealthTrio	mPulse	M&A	N/D	Both acquisitions reinforce mPulse's commitment to revolutionizing patient and member engagement while improving health outcomes
Dec-23	Advent Health Partners	TREND Health Partners	M&A	N/D	Offers an Al-driven platform that identifies and standardizes clinical attributes from itemized bills and medical records
Dec-23	Ametros	Webster Bank	M&A	N/D	Provides post-settlement medical administration of medical funds from insurance claim settlements
Dec-23	Carisk Partners	Lee Equity Partners / Elements	M&A	N/D	Provides specialty risk transfer and care-coordination for insurers, government entities and self-insured plan sponsors
Oct-23	PrecisionGx	TREND Health Partners	M&A	N/D	Provides next-generation artificial intelligence and machine learning solutions to improve payment accuracy of health insurance claims

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

<sup>2.</sup> M&A Transaction Value represents Enterprise Value at announcements


The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and
includes companies based outside the United States – "Nasdaq"

Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – "S&P 500"

Driven by your success.

## **Next-Gen Primary Care Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Nov-23	Forward Health	Khosla Ventures / Founders Fund / Softbank	Series E	\$100	Offers primary care that combines advanced diagnostics, personalized health plans and a tech-enabled in-person health experience
Oct-23	Pair Team	NEXT Ventures	Series A	\$9	Virtual and community-based primary care solution connecting Medicaid's highest-risk patients to high-quality care
Oct-23	Greater Good Health	Flare Capital	Series A	\$20	Offers primary care through a value-based care model improving quality and cost of care for senior citizens
Oct-23	Waymark	Lux Capital / CVS Health	Capital Raise	\$42	Offers a tech-enabled, community-based care platform for primary care providers and patients enrolled in Medicaid
Oct-23	Main Street Health	Oak HC/FT	Capital Raise	\$315	Partners with primary care clinics in rural America providing clinics with staff, tech and opportunities to improve the quality and access to care

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

M&A Transaction Value represents Enterprise Value at announcements

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdaq"

 $Standard \ and \ Poor's 500 \ Index \ is \ a \ capitalization-weighted \ index \ of 500 \ stocks. The \ index \ is \ designed \ to \ measure \ performance \ of the$ 

broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the secondA Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to

## **Provider Overview**

## **Public Peer Group Performance**



#### **Select Recent Transactions**

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Туре	Value (M) <sup>2</sup>	Target Description
Dec-23	Acclara	R1 RCM	M&A	\$675	Provides revenue cycle management solutions that enhance cash flow, reduce administrative complexities and ensure compliance
Dec-23	Ludi	Great Point Partners	Growth Investment	N/D	Provides a platform that optimizes the entire payment process between hospitals and physicians $$
Nov-23	Harmony Healthcare IT	Novacap	Growth Investment	N/D	Offers data archiving and management solutions including retention, conversion and migration
Nov-23	•SPM Group	Unlock Health	M&A	N/D	Offers a full-service digital and traditional marketing platform with a focus on the hospital and health system market
Oct-23	Hallmark Health Care Solutions	Summit Partners	Growth Investment	N/D	Provides a platform for hospitals and health systems to streamline talent sourcing and deployment

the left of the chart. Performance is market cap-weighted

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 12/31/23; Projections based off consensus analyst estimates

Selected investors

M&A Transaction Value represents Enterprise Value at announcements

Indicates a Canaccord Genuity-led transaction

The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Nasdaq stock exchange and the stocks traded on the Stockincludes companies based outside the United States - "Nasdag"

 $Standard \ and \ Poor's 500 \ Index \ is \ a \ capitalization-weighted \ index \ of 500 \ stocks. The \ index \ is \ designed \ to \ measure \ performance \ of the$ 

broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries - "S&P 500" and the second properties of the secondA Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to



# **Select Q4'23 Transactions**

Appendix



## **Select Q4'23 M&A Transactions**

Ann.				Enterprise	EV	/
Date	Target	Acquiror	Sub-sector	Value	LTM Rev. <sup>1</sup>	LTM EBITDA <sup>1</sup>
Dec-23	MEDHOST	Constellation Software	Provider	N/D	N/D	N/D
Dec-23	HealthTrio	mPulse	Payor	N/D	N/D	N/D
Dec-23	Decision Point	mPulse	Payor	N/D	N/D	N/D
Dec-23	GlobalData Healthcare Division	Inflexion	Provider	\$1,413	11.6x	22.3x
Dec-23	Verustat	CoachCare	Provider	N/D	N/D	N/D
Dec-23	Advent Health Partners	TREND Health Partners	Payor	N/D	N/D	N/D
Dec-23	Ametros	Webster Bank	Payor	\$350	N/D	N/D
Dec-23	Adivo	Herspiegel	Pharma	N/D	N/D	N/D
Dec-23	Worldwide Clinical Trials	Kohlberg & Company	Pharma	N/D	N/D	N/D
Dec-23	CancerLinQ	ConcertAl	Provider	N/D	N/D	N/D
Dec-23	Aventine Consulting	Prime Global Medical Communications	Pharma	N/D	N/D	N/D
Dec-23	LifeOmic	Fountain Life	Provider	N/D	N/D	N/D
Dec-23	Acclara	R1RCM	Provider	\$675	2.3x	26.9x
Dec-23	MyACTome	HOPCo	Virtual Care and Digital Health	N/D	N/D	N/D
Dec-23	Valant	Resurgens Technology Partners	Provider	N/D	N/D	N/D
Dec-23	Revive Marketing	BPD	Provider	N/D	N/D	N/D
Dec-23	Carisk Partners	Lee Equity Partners / Elements	Payor	N/D	N/D	N/D
Nov-23	Wave HDC	Experian Health	Provider	N/D	N/D	N/D
Nov-23	Autoscribe Informatics	Xybion	Pharma	N/D	N/D	N/D
Nov-23	TRC Healthcare	Colibri Group	Provider	N/D	N/D	N/D
Nov-23	CrowdPharm / Hot Iron Health	Spectrum Science	Pharma	N/D	N/D	N/D
Nov-23	Fern Health	BehaVR	Virtual Care and Digital Health	N/D	N/D	N/D
Nov-23	YouScript	Aranscia	Pharma	N/D	N/D	N/D
Nov-23	• SPM Group	Unlock Health	Provider	N/D	N/D	N/D
Nov-23	Cloudbreak Health	GTCR	Virtual Care and Digital Health	\$180	2.4x	N/D
Nov-23	Sitka	AristaMD	Virtual Care and Digital Health	N/D	N/D	N/D
Nov-23	Minded	UpLift	Virtual Care and Digital Health	N/D	N/D	N/D
Nov-23	IntegriChain	Nordic Capital	Pharma	N/D	N/D	N/D
Nov-23	Community Family Care Medical Group	Apollo Medical Holdings	Next-Gen Primary Care	<b>\$202</b> <sup>2</sup>	1.1x	8.1x
Nov-23	ActiveRADAR	Surescripts	Pharma	N/D	N/D	N/D
Nov-23	Naring Health	Viome	Virtual Care and Digital Health	N/D	N/D	N/D

Source: Company filings and press releases

Note: \$USD in millions

<sup>1.</sup> Last twelve months – "LTM"

EV includes earnout

Indicates a Canaccord Genuity-led transaction

## **Select Q4'23 M&A Transactions (cont.)**

Ann.				Enterprise	EV/	
Date	Target	Acquiror	Sub-sector	Value	LTMRev.	LTMEBITDA
Nov-23	PatientCentra	SubjectWell	Pharma	N/D	N/D	N/D
Nov-23	SentryHealth	First Stop Health	Employer	N/D	N/D	N/D
Nov-23	Electronic Registry Systems	Health Catalyst	Provider	N/D	N/D	N/D
Nov-23	ConcentricLife	Accenture	Pharma	\$245	N/D	N/D
Oct-23	Olive Al	Waystar / Humata Health	Provider	N/D	N/D	N/D
Oct-23	AQuity Solutions	IKS Health	Provider	\$200	N/D	N/D
Oct-23	Digital Diagnostic Imaging	Kingsway	Provider	\$11	2.6x	6.1x
Oct-23	CAE Healthcare Business	Madison Industries	Provider	\$226	1.6x	N/D
Oct-23	EngageSmart	Vista Equity Partners	Provider	\$3,679	10.1x	NMF
Oct-23	AllStripes	Picnic Health	Pharma	N/D	N/D	N/D
Oct-23	PrecisionGx	TREND Health Partners	Payor	N/D	N/D	N/D
Oct-23	True North	JPA Health	Pharma	N/D	N/D	N/D
Oct-23	The Curry Rockefeller Group	Citrus Health Group	Pharma	\$27	N/D	N/D
Oct-23	Pre-Intent	Home Care Plus	Provider	N/D	N/D	N/D
Oct-23	MD Consents	Engaged MD	Provider	N/D	N/D	N/D
Oct-23	Viewgol	CPSI	Provider	\$68 <sup>1</sup>	N/D	<b>15.0x</b> <sup>2</sup>
Oct-23	Evry Health	Globe Life	Payor	N/D	N/D	N/D
Oct-23	Corridor	Wellsky	Provider	N/D	N/D	N/D
Oct-23	Envera Health	Access Healthcare	Provider	\$32	N/D	N/D
Oct-23	<ul><li>Medicx Health</li></ul>	OptimizeRx	Pharma	\$95	N/D	N/D
Oct-23	Flume Health's TPA Operations	Vitori Health	Payor	N/D	N/D	N/D
Oct-23	Bright.MD's Technology Platform	Evernorth Health	Virtual Care and Digital Health	N/D	N/D	N/D
Oct-23	Dawn Health's Virtual Care Platform	Health Care Originals	Virtual Care and Digital Health	N/D	N/D	N/D
Oct-23	Boston Software Systems	LGI Healthcare	Provider	N/D	N/D	N/D
Oct-23	Excite Health's HIM Division	ECLAT Health	Provider	N/D	N/D	N/D
Oct-23	Hybrid Healthcare Communications	Health & Wellness Partners	Pharma	N/D	N/D	N/D
Oct-23	Netalytics	Netsmart	Provider	N/D	N/D	N/D
Oct-23	Medical Record Accociates	GeBBS Healthcare Solutions	Provider	N/D	N/D	N/D
Oct-23	Commure	Athelas	Provider	N/D	N/D	N/D
Oct-23	HCPro	AHIMA	Provider	N/D	N/D	N/D
Oct-23	RCxRules	Alpha II	Provider	N/D	N/D	N/D

Source: Company filings and press releases

17

Note: \$USD in millions

<sup>1.</sup> EV includes earnout

## **Disclosures**

18

This material is provided for information purposes only and is intended for distribution in those jurisdictions where subsidiaries of Canaccord Genuity Group Inc. (together, "Canaccord Genuity") are registered as advisors or dealers in securities. Any distribution or dissemination of this material in any other jurisdiction is strictly prohibited. The information does not constitute an offer or solicitation in any jurisdiction in which such an offer or solicitation is not authorized, or to any person to whom it is unlawful to make such an offer or solicitation. This is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs to any person. Clients should obtain advice based on their own individual circumstances before making an investment decision. Any client wishing to effect any transactions should do so through a Canaccord Genuity qualified salesperson in their jurisdiction of residence.

The information contained herein has been compiled by Canaccord Genuity from sources believed to be reliable, but no representation or warranty, express or implied, is made by Canaccord Genuity or any other person to its fairness, accuracy, completeness or correctness. To the fullest extent permitted by law, neither Canaccord Genuity nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained herein.

All material presented in this document, unless specifically indicated otherwise, is under trademark and copyright to Canaccord Genuity. None of the material, or its content, or any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of Canaccord Genuity.

Note to Readers: This report was created by members of the investment banking department of Canaccord Genuity LLC ("Canaccord" or "Canaccord Genuity") and has not been reviewed by or discussed with any members of the Canaccord Genuity research department. This report is not intended to be, and in no way constitutes, a "research report," as such term is defined by Rule 137 promulgated under the Securities Act of 1933, as amended. Canaccord Genuity's investment banking department has done, and may continue to do, business with companies included in this report. This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. This report is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to corporate and institutional clients and does not have regard for the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, neither Canaccord Genuity, its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this report. Past performance is not indicative of future results. Canaccord Genuity LLC is a registered broker-dealer regulated by the SEC and FINRA. Member SIPC. Offices in other countries are offices of other companies in the Canaccord group of companies. See <a href="https://www.canaccordgenuity.com/investor-re

Copyright © Canaccord Genuity Corp. 2023. – Member CIRO/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited 2023. – Member of the London Stock Exchange, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2023. – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited 2023. – Authorized and regulated by ASIC.

#### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This document may contain certain "forward-looking information" (as defined under applicable securities laws). These statements relate to future events or future performance and include management's expectations, beliefs, plans, estimates, intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts, business and economic conditions and Canaccord Genuity Group LLC's (the "Company") growth, results of operations, market position, ability to compete and future financial or operating performance of the Company, performance and business prospects and opportunities. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue", "target", "intend", "could" or the negative of these terms or other comparable terminology. By its very nature, forward-looking information involves inherent risks and uncertainties, both general and specific, and a number of factors could cause actual events or results to differ materially from the results discussed in the forward-looking information. In evaluating these statements, readers should specifically consider various factors, which may cause actual results to differ materially from any forward-looking statement. These factors include, but are not limited to, market and general economic conditions, the nature of the financial services industry, the risks and uncertainties discussed from time to time in the Company's interim and annual consolidated financial statements and its Annual Information Form filed on <a href="https://www.sedar.com">www.sedar.com</a>. Readers are cautioned that the preceding list of material factors or assumptions is not exhaustive. Except as may be required by applicable law, the Company does not und